non-bcr-abl1 molecular biomarkers of prognosis in cml
Published 1 year ago • 61 plays • Length 18:21Download video MP4
Download video MP3
Similar videos
-
5:41
bcr-abl1-targeted tkis in treatment of cml
-
33:30
standardisation of bcr::abl1 measurement in cml: lessons learned
-
46:08
genomics & mutations in cml - risk & assessment
-
2:51
the genetic complexity of cml beyond bcr-abl1 & the clinical impact of additional abnormalities
-
24:05
mechanisms of disease progression in chronic myeloid leukemia
-
31:06
novel biomarker module six - result interpretation
-
8:00
chronic myeloid leukemia etiology. mechanism of tyrosine kinase pathway how bcr-abl1 is formed
-
20:58
knowledge centre - from the lab - non-clinical - drug resistance testing
-
42:37
icmlf conversation: cml highlights of ash 2022 - biological overview
-
8:24
cml: factors in selecting a bcr-abl tki
-
1:05:16
icmlf conversation: cml highlights of eha 2022 - biological and clinical overview
-
1:59
dr. erba on bcr-abl ratios in patients with cml
-
1:12
abl001 – a new bcr-abl inhibitor for chronic myeloid leukemia (cml) treatment
-
2:12
bcr-abl1 and the philadelphia chromosome - part 1: normal and aberrant karyograms
-
1:39:04
#18 genewise expert talk: genomic based risk assessment in cml
-
1:05
covalent-101: bmf-219 in patients with r/r aml, dlbcl & multiple myeloma
-
6:08
combining and sequencing bcr-abl tkis with omacetaxine in cml
-
1:39:04
genomic based risk assessment in cml
-
0:48
advances in non-covalent btk inhibitors for cll: bruin study update